KalVista Pharmaceuticals, Inc. Segments Disclosure
Note 15: Segment Information
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”) in deciding how to allocate resources and assess performance. The Company operates in one business segment. The Company’s CODM is its , who reviews financial information presented on a consolidated basis. The CODM’s financial review is focused on the consolidated financial results of the Company which is used as the basis for financial performance assessment and allocation of resources.
The following table presents selected financial information with respect to the Company’s single operating segment for the years ended April 30, 2025 and April 30, 2024 (in thousands):
|
Years Ended |
|
|||||
|
April 30, |
|
|||||
|
2025 |
|
|
2024 |
|
||
Operating Expenses: |
|
|
|
|
|
||
Clinical development |
|
43,166 |
|
|
|
46,520 |
|
Research |
|
19,713 |
|
|
|
36,074 |
|
Regulatory & QA |
|
8,830 |
|
|
|
3,573 |
|
Pre-commercial planning |
|
62,859 |
|
|
|
18,481 |
|
Other G&A |
|
53,427 |
|
|
|
35,797 |
|
Total operating expenses |
|
187,995 |
|
|
|
140,445 |
|
(Loss) income from operations |
|
(187,995 |
) |
|
|
(140,445 |
) |
Interest and other income (expense), net |
|
7,943 |
|
|
|
13,801 |
|
(Loss) income before income taxes |
|
(180,052 |
) |
|
|
(126,644 |
) |
Provision for (benefit from) for income taxes |
|
3,392 |
|
|
|
- |
|
Net loss |
|
(183,444 |
) |
|
|
(126,644 |
) |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.